Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders

Table 3 Changes in aberrant behaviors of children assessed with the ABC-J

Subscales	Visits^a	Changes^b				Wilcoxon’s signed rank sum test^c
		n	Q1	Median	Q3	P value
I (irritability)	2	–	–	–	–	–
	5	99	−4	0.0	2	0.1197
	9	97	−5	−1.0	2	0.0094
II (lethargy)	2	–	–	–	–	–
	5	99	−3	0.0	3	0.5533
	9	97	−4	−1.0	3	0.1267
III (stereotypic behavior)	2	–	–	–	–	–
	5	99	−2	0.0	0	0.0322
	9	97	−2	0.0	1	0.1035
IV (hyperactivity)	2	–	–	–	–	–
	5	99	−5	0.0	4	0.5504
	9	97	−6	−1.0	2	0.0025
V (inappropriate speech)	2	–	–	–	–	–
	5	99	−1	0.0	1	0.3078
	9	97	−2	0.0	1	0.0125

^a: visit 2 = end of the screening phase; visit 5 = week 10 of the medication phase II; visit 9 = week 26 of the medication phase II
^b: Change = (measured value at each visit) - (measured value at visit 2)
^c: Comparison against visit 2
ABC-J Aberrant Behavior Check List-Japanese version

ISSN: 1471-244X